The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor…
The Chase Group Secures the Vice President, Global Head of Data Sciences for Genmab
The Chase Group is pleased to announce the successful completion of the Vice President, Global Head of Data Sciences search at Genmab. A scientist with…
A Successful Placement at Eisai, Inc.
The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board…
Another Successful Placement by The Chase Group at Marinus Pharmaceuticals
The Chase Group is pleased to announce the successful completion of the Executive Director, Head of Clinical Development Operations search at Marinus Pharmaceuticals. The successful…
Another Key Placement by The Chase Group
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer. We are so proud to connect life-changing executives and companies!-
The Chase Group Successfully Completes Vice President, Clinical Development, Respiratory for Ionis Pharmaceuticals
The Chase Group appreciates and values our continued partnership with Ionis Pharmaceuticals and is pleased to announce the successful completion of the Vice President, Clinical…